Ragaie Maha H, Mohammed Shimaa E, Shehata Shimaa S
Department of Dermatology, STD's and Andrology, Faculty of Medicine, Minia University, Minya, Al, Egypt.
J Cosmet Laser Ther. 2024 Nov 16;26(5-8):89-93. doi: 10.1080/14764172.2024.2389275. Epub 2024 Aug 14.
Alopecia areata (AA) is a common autoimmune -cell mediated non-scarring, form of hair loss. It affects people of all ages and sexes.
To compare the efficacy of intralesional vitamin D3 injection versus that of intralesional triamcinolone acetonide in the treatment of patchy alopecia areata.
This clinical study was carried on 40 adult patients with patchy alopecia areata, the patients were categorized into two groups. Group I involved 20 patients who received 1 ml of intralesional injection of vitamin D3 (cholecalciferol aqueous preparation 200 000 IU/2 ml) every 4 weeks for a maximum of three sessions. Group II involved 20 patients who received 1 ml of intralesional injection of triamcinolone acetonide 40 mg/mL every 4 weeks for a maximum of three sessions. Clinical and trichoscopic evaluations were done at the baseline, each session and for 3 months after the last session.
There was no statistically significant difference between the two studied groups regarding the degree of clinical improvement ( = .8). A statistically significant reduction in AA specific trichoscopic signs was detected at the end of the sessions and after 3 months of follow-up in both groups, without any statistically significant difference between them. Also a statistically significant difference was found between both groups regarding the reported adverse effects with a significant better patient satisfaction encountered toward the intralesional vitamin D3 injection.
Intralesional vitamin D3 is a promising effective, simple, safe, and inexpensive, therapeutic modality for patchy AA.
斑秃(AA)是一种常见的自身免疫性细胞介导的非瘢痕性脱发形式。它影响所有年龄和性别的人群。
比较皮损内注射维生素D3与皮损内注射曲安奈德治疗斑秃的疗效。
本临床研究针对40例成年斑秃患者展开,将患者分为两组。第一组20例患者,每4周接受1毫升皮损内注射维生素D3(胆钙化醇水剂200000国际单位/2毫升),最多注射三次。第二组20例患者,每4周接受1毫升皮损内注射40毫克/毫升曲安奈德,最多注射三次。在基线、每次注射时以及最后一次注射后3个月进行临床和毛囊镜评估。
两组在临床改善程度方面无统计学显著差异(P = 0.8)。两组在注射结束时和随访3个月后,斑秃特异性毛囊镜体征均有统计学显著降低,且两组之间无统计学显著差异。此外,两组在报告的不良反应方面存在统计学显著差异,患者对皮损内注射维生素D3的满意度明显更高。
皮损内注射维生素D3是治疗斑秃的一种有前景的有效、简单、安全且廉价的治疗方式。